EUROPE INFERTILITY TESTING AND TREATMENT MARKET FORECAST 2018-2026

EUROPE INFERTILITY TESTING AND TREATMENT MARKET FORECAST 2018-2026

  • January 2018 •
  • 89 pages •
  • Report ID: 5304124
KEY FINDINGS
Europe infertility testing and treatment market captured the highest revenue share of the global market in 2017 by generating $6190.90 million. The market is expected to lead throughout the forecast period of 2018-2026, by exhibiting a CAGR of 6.12% and collecting a net total of $10494.53 million.

MARKET INSIGHTS
Globally, Europe is the largest market for infertility. Although the U.K market accounted for a dominant market share in 2017, other countries such as Germany, Spain, France, Nordics and Russia are fast catching up. In fact, the Nordics are expected to showcase the highest CAGR over the forecast period.

The Nordic region has been a destination for fertility tourism for most couples from Europe, North America, Kenya and Hong Kong. The German infertility testing and treatment is the second fastest growing market in Europe. Increasing success rates of the IVF treatments within the region has led to significant growth in this market.

COMPETITIVE INSIGHTS
Companies like Integrated Genetics, Thermo Fisher Scientific Inc, Ovascience, Esco Micro Pte. Ltd, Halotech DNA, Genea, Roche, Irvine Scientific, Ferring Pharmaceuticals, The Cooper Companies Inc, Quest Diagnostic, Origio, Illumina Inc, Andrology Solutions, Vitrolife Ab, Centogene, Celmatrix, Merck, Elucigene, LabCorp and Endo Pharmaceuticals are well established in this region.
Country=Europe Date=201801 Publisher=InkwoodResearch Price=2000